News | Antiplatelet and Anticoagulation Therapies | March 14, 2017

Most Atrial Fibrillation Patients Do Not Get Preventive Drug Before Stroke

Duke study finds only 16 percent of afib patients had received recommended anticoagulation medication prior to having a stroke; more than two-thirds of all patients had no documented reason for not receiving proper medication

warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke

March 14, 2017 — More than 80 percent of stroke patients with a history of atrial fibrillation either received not enough or no anticoagulation therapy prior to having a stroke, according to a Duke Clinical Research Institute study. This revelation comes despite the drugs’ proven record of reducing stroke risk.

Reporting in the March 14 issue of the Journal of the American Medical Association, the researchers also found that when patients did receive recommended anticoagulation drugs, they had less severe stroke outcomes and less risk of dying.

“Atrial fibrillation is very common, and people with the condition are at a much higher risk of having stroke,” said lead author Ying Xian, M.D., Ph.D., assistant professor of neurology at Duke and member of the Duke Clinical Research Institute. “Treatment guidelines call for these patients to receive an anticoagulant such as warfarin at a therapeutic dose or a non-vitamin K antagonist oral anticoagulant (NOAC), so it’s surprising that this is not occurring in the vast majority of cases that occur in community settings.”

The study included more than 94,000 patients with atrial fibrillation from the American Heart Association’s “Get With The Guidelines-Stroke” registry who had had an acute ischemic stroke. The analysis was sponsored by the Patient-Centered Outcomes Research Institute to inform patients, physicians and others about optimal stroke care.

The researchers found that only 16 percent of patients with atrial fibrillation had received the recommended anticoagulation medication prior to having a stroke. These medications include therapeutic levels of warfarin or NOAC.

A total of 84 percent of patients were not treated according to the guidelines prior to stroke:

  • Thirty percent were not taking any antithrombotic treatment at all;
  • Forty percent were taking an antiplatelet drug such as baby aspirin or clopidogrel; and
  • Thirteen-point five percent were on warfarin, but at a level that was not considered therapeutic at the time of their stroke.

“While some of these patients may have had reasons for not being anticoagulated, such as high bleeding or fall risk, more than two-thirds had no documented reason for receiving inadequate stroke prevention therapy,” Xian said.

Xian added that in those rare cases where anticoagulation failed to prevent a stroke, patients who were taking the therapy showed a tendency to have less severe strokes, with less disability and death.

“These findings highlight the human costs of atrial fibrillation and the importance of appropriate anticoagulation,” Xian said. “Broader adherence to these atrial fibrillation treatment guidelines could substantially reduce both the number and severity of strokes in the U.S. We estimate that between 58,000 to 88,000 strokes might be preventable per year if the treatment guidelines are followed appropriately.”

In addition to Xian, study authors include Emily C. O’Brien, Li Liang, Haolin Xu, Lee H. Schwamm, Gregg C. Fonarow, Deepak L. Bhatt, Eric E. Smith, DaiWai M. Olson, Lesley Maisch, Deidre Hannah, Brianna Lindholm, Barbara L. Lytle, Michael J. Pencina, Adrian F. Hernandez, and Eric D. Peterson.

This received funding support from the Patient-Centered Outcomes Research Institute (CE-1304-7073).

Read the article "Advantages and Disadvantages of Novel Oral Anticoagulants."

Medication Adherence a Problem in Atrial Fibrillation Patients

For more information: www.www.jamanetwork.com

Related Content

Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...